Michael Grossbard is an Oncology physician affiliated with NYU Langone Health. OpenAlex indexes 171 publications with 6,218 citations (h-index 41); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1000 10th Ave Fl 11
Suite 11c02
New York, NY 100191147
Telephone
212-523-5419Registry record last updated 29 Nov 2012.
Clinical trials
- Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Acrotech Biopharma LLCProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
46.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor46.8%Acyclovir100%Part D<11 patientsCancer & immunology
29.8%Aromatase Inhibitor29.8%Anastrozole100%Part D<11 patientsAnti-infectives
23.4%Short-acting sulfonamides23.4%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Early-Stage Classic Hodgkin Lymphoma: The Utilization of Radiation Therapy and Its Impact on Overall Survival
International Journal of Radiation Oncology*Biology*Physics
2015 - Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy
Leukemia & lymphoma/Leukemia and lymphoma
2014 - Impact of Oncology Drug Shortages on Patient Therapy: Unplanned Treatment Changes
Journal of Oncology Practice
2013
Similar KOLs
Other experts from the same institution or the same specialty.
Harvey Pass, MD
NYU Langone Health
Gareth Morgan, MD
NYU Langone Health
Douglas Kondziolka, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”